MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study
Key facts
- Who runs it
- Boston Medical Center
- Where
- Boston and Carrboro, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- People taking part
- 46 people enrolled
- Started
- 1 Dec 2018
- Ended
- 8 May 2024
- Type of study
- Observational, 3 groups
- Treatments tested
- Pharmacokinetic analysis
- Safety and Efficacy
- Genetic and epigenetic analysis
- Breast milk analysis
- Record updated
- 4 November 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Pregnant women between 6 - 30 6/7 weeks gestation, receiving prenatal care at Boston Medical Center (BMC) or the University of North Carolina (UNC)
- Plan to deliver infant at BMC or UNC
- Diagnosis of opioid use disorder (OUD) or alcohol use disorder (AUD) in the current pregnancy on prescribed oral or extended-release naltrexone; or buprenorphine/naloxone for the treatment of OUD
- English speaking
- Singleton pregnancy
Who cannot take part
- OUD on prescribed methadone, or no maintenance medication
- Severe psychiatric illness or cognitively impairing ability to provide informed consent
- OUD on Subutex formulation of buprenorphine
- Current maternal incarceration
- Women who present for care >31 0/7 weeks
- Multiple gestation pregnancy
Where in United States
- Boston Medical CenterBoston, United States
- University of North Carolina-Chapel HillCarrboro, United States
About the trial
What the trial wants to find out
This is a multi-center prospective comparative cohort study examining the safety, efficacy, pharmacokinetics, and pharmacogenomics of naltrexone for pregnant women with opioid use disorder. Pregnancy, delivery, and maternal and infant outcomes to 12 months post-delivery will be examined and compared with a cohort treated with buprenorphine/naloxone.
The 3 groups in the trial
- Naltrexone
Pregnant women with opioid use disorder on prescribed oral or extended-release naltrexone and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This group will also receive safety and efficacy interventions.
Treatment: Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis, and Breast milk analysis
- Buprenorphine/Naloxone
Pregnant women with opioid use disorder on prescribed buprenorphine/naloxone and their infants. Biospecimens collected from this group will undergo genetic and epigenetic analysis and the group will also receive safety and efficacy interventions.
Treatment: Safety and Efficacy and Genetic and epigenetic analysis
- Naltrexone - alcohol use disorder
Pregnant women with alcohol use disorder on prescribed naltrexone (oral or extended-release) and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This exploratory group will also receive safety and efficacy interventions.
Treatment: Pharmacokinetic analysis, Genetic and epigenetic analysis, and Breast milk analysis
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety, Efficacy, Pharmacokinetics, and Pharmacogenomics of Extended-Release Naltrexone in Pregnant Women
- Record updated
- 4 November 2024